HGH Fragment 176-191 Dosage Guide: Protocols, Calculator & Safety

Starter protocol (cycles 1-2, establishing tolerance and baseline response): 250 mcg subcutaneously, 5 days per week, for 8 weeks.

This protocol assumes the user has made an informed decision to proceed with AOD-9604 despite the failed pivotal trial data and absence of regulatory approval. It is designed to minimise risk during initial exposure while providing a reasonable trial of the compound.

Prerequisites before starting:

1. Confirm obesity/overweight status genuinely warrants pharmacological intervention — BMI ≥30 or BMI ≥27 with comorbidity is the standard threshold. If BMI is <25 and the goal is aesthetic body recomposition, AOD-9604 is unlikely to produce meaningful results and the risk-benefit calculation shifts unfavourably.
2. Consider evidence-based alternatives first — has a GLP-1 agonist been discussed with your physician? Structured diet/exercise program attempted with documented adherence? If these paths have not been exhausted, AOD-9604 is premature.
3. Source verification — obtain AOD-9604 only from reputable compounding pharmacies with USP-compliant formulation OR from research-chemical vendors with third-party certificates of analysis (HPLC, mass spectrometry).
4. Baseline assessment — current weight, waist circumference, body composition (DEXA if available), fasting glucose, HbA1c, lipid panel, TSH, basic metabolic panel, liver function tests, and a baseline resting metabolic rate if possible.
5. Lifestyle framework — AOD-9604 without concurrent caloric restriction, resistance training, and adequate protein intake is unlikely to produce meaningful body composition change. Have this framework in place before starting.

Dosing:

• 250 mcg subcutaneously, once daily in the morning on a fasted stomach.
• Five days per week (typical schedule: Monday-Friday, with Saturday-Sunday off). Some protocols use 5-on-2-off or 6-on-1-off; the specific pattern is not evidence-based.
• Inject into subcutaneous abdominal, thigh, or flank tissue using a 29-31 gauge insulin syringe. Rotate sites to avoid local irritation.
• Timing: most protocols recommend fasted morning administration, 30-60 minutes before any caloric intake. Some protocols use pre-workout dosing for training days.

Reconstitution:

• AOD-9604 is supplied as lyophilised powder in vials typically containing 2 mg or 5 mg.
• Reconstitute with bacteriostatic water (0.9% benzyl alcohol in water for injection) to a working concentration of typically 1 mg/mL (e.g., 2 mg vial + 2 mL bac water = 1000 mcg/mL).
• 250 mcg = 0.25 mL at 1 mg/mL concentration.
• Store reconstituted vial refrigerated (2-8°C). Use within 4-6 weeks of reconstitution.

Monitoring during the 8-week cycle:

• Weekly: weight, waist circumference, subjective energy/mood/sleep/hunger notes, injection-site observation.
• Every 2 weeks: photographs in consistent lighting and pose for visual body composition tracking.
• End of week 8: repeat fasting glucose, HbA1c, lipid panel, body composition measurement.

What to expect:

• Most users report no dramatic acute effects.
• Subjective fat-loss perception (particularly abdominal) may begin to appear in weeks 4-8.
• Hunger, energy, and mood effects are typically minimal.
• Any weight loss observed is likely driven primarily by the concurrent lifestyle program, with any AOD-9604-specific contribution being small.

Stopping criteria:

• Persistent injection-site reaction unresponsive to site rotation.
• Allergic symptoms.
• Any concerning symptom you would take seriously on a prescription medication.
• No observable effect after 8 weeks — AOD-9604 is unlikely to work for you.

Post-cycle: 4-8 week break before considering a second cycle. Assess lifestyle, progress, and whether continuing is worthwhile.

Intermediate protocol (cycles 3+, for users who tolerated the starter protocol and perceived subjective benefit): 500 mcg subcutaneously, 5 days per week, for 12 weeks, with optional GH secretagogue stacking.

This protocol is for users with established AOD-9604 tolerance from prior cycles who want a longer, slightly higher-dose cycle. It should NOT be a first cycle.

Dosing:

• 500 mcg subcutaneously daily on the 5-days-on schedule.
• Split dosing option: 250 mcg morning + 250 mcg pre-workout/evening — unclear whether this is superior to single morning dosing, but some users prefer the split.
• Duration: 12 weeks, with structured break afterward.

Stacking at the intermediate level (optional, one at a time):

• CJC-1295 no DAC + ipamorelin combination, typically 100 mcg of each peptide 2-3 times daily, timed pre-meal and pre-bed. This adds GH secretagogue activity to the regimen. User reports commonly describe this as producing better sleep and more pronounced body composition changes than AOD-9604 alone, though controlled data are absent.
• Tesamorelin — an FDA-approved GHRH analog for HIV-associated lipodystrophy. Off-label use for general visceral fat reduction has a better evidence base than AOD-9604 (Falutz et al., NEJM 2007, PMID: 18024865 in HIV lipodystrophy). However, tesamorelin requires prescription in the US and has its own side-effect and regulatory considerations.
• GLP-1 agonists — if the goal is meaningful weight loss and the user meets BMI criteria, adding semaglutide (initiated at 0.25 mg weekly, titrated) produces effect sizes orders of magnitude larger than AOD-9604 alone. Requires prescription and physician oversight.

Enhanced monitoring at intermediate doses:

• Every 4 weeks: fasting glucose, HbA1c (if stacking with GH secretagogues, which can affect glucose metabolism), lipid panel.
• Every 4 weeks: subjective wellness assessment, sleep quality, energy, libido, appetite.
• Mid-cycle (week 6-8): body composition assessment (DEXA if possible, or consistent methods).
• End of cycle: full blood panel including CBC, CMP, liver function tests, IGF-1 (especially if stacking with GH secretagogues — baseline vs. on-cycle IGF-1 informs whether GH stimulation is occurring and at what level).

Lifestyle emphasis intensifies at intermediate doses:

• Caloric deficit of 300-500 kcal/day during the cycle.
• Protein intake 1.6-2.2 g/kg body weight/day to preserve lean mass.
• Resistance training 3-4x/week minimum.
• Sleep 7-9 hours/night.
• Cardiovascular exercise 150+ min/week.
• The lifestyle program is doing the real work; the peptide is potentially adjunctive.

Cycle structure:

• 12 weeks on.
• 8-12 weeks off.
• Reassess whether continuing cycles is worthwhile based on results, side effects, cost, and whether evidence-based alternatives should be prioritised.

Stopping criteria:

• Any safety-relevant symptom.
• Plateau of body composition changes despite full lifestyle adherence — the peptide is not contributing usefully.
• Shift in goals toward significant weight loss — time to discuss GLP-1 agonists with your physician.

Honest check-in at the intermediate stage: after 2-3 cycles of AOD-9604, users who have not seen meaningful body composition change should consider that the clinical trial failure may be relevant to their experience. Not every peptide works for every user, and AOD-9604's failed Phase 2b trial suggests the signal is genuinely small. Continuing to chase a small effect for multiple cycles may not be the best use of time, money, or injection-site real estate.

Advanced protocol (experienced peptide users, 5+ cycles of AOD-9604 or established long-term peptide practice): 500-750 mcg daily, continuous dosing with planned breaks, integrated with comprehensive peptide and lifestyle program.

This protocol is for experienced users who have well-established body recomposition practices, have trialled AOD-9604 extensively, and have realistic expectations about the compound's modest effects. It does NOT represent an evidence-based escalation path and should be approached with the understanding that all of this sits well outside the boundaries of controlled clinical data.

Dosing:

• 500-750 mcg subcutaneously daily. Higher doses do not have a clear rationale from the mechanism-of-action data or the failed clinical trials.
• Continuous daily dosing vs. 5-days-on — no clear evidence favouring one approach; some advanced protocols use 6 days on, 1 day off.
• Long cycles: 16-20 weeks, with structured breaks of 4-8 weeks between cycles.

Comprehensive advanced stack (illustrative, not endorsed):

• AOD-9604 500-750 mcg daily (direct lipolytic)
• CJC-1295 no DAC 100 mcg + ipamorelin 100 mcg, 3x daily (GH secretagogue axis)
• Tesamorelin 1 mg daily subcutaneously (evidence-based GHRH analog, prescription)
• Semaglutide or tirzepatide at established doses (evidence-based weight loss)
• BPC-157 250 mcg twice daily (anecdotal tissue repair)
• TB-500 2-5 mg weekly (anecdotal tissue repair)
• Plus comprehensive lifestyle: structured resistance training, protein-optimised diet, sleep hygiene, aerobic conditioning.

This stack is extensive and expensive. The evidence base supporting each additional component is variable, and the marginal benefit of adding each additional peptide on top of an already-effective GLP-1 regimen is unlikely to justify the cost or complexity. This pattern reflects what exists in some body-recomposition clinics but is not an evidence-based medical recommendation.

Advanced monitoring:

• Quarterly: comprehensive metabolic panel, CBC, lipid panel, HbA1c, TSH, IGF-1, testosterone (total and free), fasting insulin, hs-CRP, vitamin D, B12.
• Biannual: body composition (DEXA preferred), resting metabolic rate, blood pressure monitoring at home.
• Annual: full physical exam with primary care or metabolic-medicine physician, with full disclosure of the peptide program.

Risks of the advanced approach:

• Polypharmacy — multiple compounds with uncharacterised interactions.
• Financial cost — hundreds to thousands of dollars per cycle.
• Opportunity cost — attention and resources directed to marginal peptides rather than foundational lifestyle factors or evidence-based pharmacotherapy.
• Lab derangement from GH stimulation — advanced protocols that raise IGF-1 carry increased glucose dysregulation and theoretical cancer-promotion risk.
• Regulatory risk — the compounding and research-peptide regulatory environment is in flux; availability and legal status of any component may change.

Exit strategy considerations: advanced peptide users should periodically step back and evaluate whether their protocol is producing results proportional to cost and complexity. If body composition is well-optimised, returning to maintenance lifestyle practices without pharmacological peptide augmentation is reasonable. If body composition is NOT well-optimised despite the advanced stack, the stack itself is not compensating for lifestyle gaps — the answer is better lifestyle practice, not more peptides.

Regulatory-pharmacy note: as of 2026, the compounding regulatory environment for AOD-9604 in the United States has tightened. Users should verify current availability and legal status before relying on compounding pharmacy supply, and should be prepared for the possibility that availability may change.